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INTRODUCTION: Invasive and non-invasive tests can be used to evaluate the activity of inflammatory bowel diseases. 
OBJECTIVE: The aim of the present study was to investigate the role of fecal calprotectin in evaluating inflammatory bowel 
disease activity and the correlation of fecal calprotectin with the erythrocyte sedimentation rate and C reactive protein values in 
inflammatory bowel disease. 
METHOD: Sixty-five patients affected with inflammatory bowel disease were enrolled. Twenty outpatients diagnosed with inflam-
matory bowel disease comprised the control group. 
RESULTS: In the present study, all patients in the control group had an fecal calprotectin value lower than the cut-off point (50 
mg/kg). 
CONCLUSION: In conclusion, fecal calprotectin was found to be strongly associated with colorectal inflammation indicating 
organic disease. Fecal calprotectin is a simple and non-invasive method for assessing excretion of macrophages into the gut lu-
men. Fecal calprotectin values can be used to evaluate the response to treatment, to screen asymptomatic patients, and to predict 
inflammatory bowel disease relapses. 
KEYWORDS: Inflammatory bowel diseases; Irritable bowel syndrome; Fecal calprotectin.
INTRODUCTION
Inflammatory bowel diseases (IBDs) are chronic 
intestinal diseases of unknown etiology that progress with 
periods of remission and activation. Invasive and non-
invasive tests can be used to evaluate the activity of these 
diseases. Among those tests, the erythrocyte sedimentation 
rate (ESR) and C reactive protein (CRP) levels are neither 
very sensitive nor very specific. Currently, the most sensitive 
and specific method is endoscopy and biopsy, but it is an 
invasive procedure. Thus, there is an increasing need for an 
easy, non-invasive and inexpensive method to evaluate the 
activity of the disease and the differential diagnosis of the 
disease in patients with irritable bowel syndrome (IBS). 
Calprotectin, first described in 1980 by Fagertol, is 
released by activated neutrophils, and it accounts for more 
than 40% of the cytosolic proteins ofneutrophils.1,2 Elevated 
concentrations of calprotectin can be measured in plasma, 
cerebrospinal fluid, synovial fluid, urine, and feces when 
ongoing inflammation is present or in malignant conditions. 
Increased fecal calprotectin (FCP) concentrations have been 
found in gastric and colorectal cancers as well as in IBD. 
The high fecal calprotectin concentrations detected in IBD 
can be explained by increased turnover of leukocytes in the 
gut wall and increased migration of neutrophils into the gut 
lumen. 
The aim of the present study was to investigate the role 
of FCP in evaluating IBD activity and remission periods and 
the correlation between FCP and CRP/ESR values in IBD.
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MATERIALS AND METHODS
Study group
This prospective study was carried out at Fatih University 
School of Medicine and Ankara University School of 
Medicine Department of Gastroenterology between February 
2006 and February 2007. Sixty-five patients affected with 
IBD (14 with Crohn’s Disease (CD) and 51 with Ulcerative 
Colitis (UC)) aged 20 to 64 years were enrolled. Twenty 
outpatients diagnosed with IBS according to Roma II criteria 
comprised the control group.3
All patients were fully informed about the objective 
of the study and agreed to participate. The study was 
approved by the Fatih University School of Medicine Ethics 
Committee.
METHODS
İBD surveillance, medical histories, and current 
treatments were all noted. Serum samples were obtained 
from all patients to measure the complete blood count, 
erythrocyte sedimentation rate (ESR), and routine 
biochemical measurements. C reactive protein (CRP) was 
measured by the nephelometric method (C-Reactive Protein 
Reagent, IMMAGE Immunochemistry Systems Beckman 
Coulter, Inc., USA). Samples obtained for FCP measurement 
were collected in disposable plastic containers and stored 
within 6 hours at -20 0C until analysis. FCP was measured 
using a commercial enzyme linked immunoassay (ELISA) 
method (Calprest, Dynex Elisa Eurospital, Trieste, Italy). 
The FCP results are expressed in mg of calprotectin per 
kilogram of wet feces within a normal reference range of 
<50 mg/kg.
Statistical analyses were performed using the SPSS 
statistical package version 11.5 for Windows. Independent-
sample T-tests were used for comparison of variables 
between groups. A p value of less than 0.05 was considered 
as statistically significant.
RESULTS
The mean ages of the participants were 41.71± 8.5 (30-
55 years) in CD patients, 40.88± 12.34 (20-69 years) in UC 
patients and 46.85± 10.57 (25-71 years) in the control group. 
Thirty-six of the inflammatory bowel disease patients were 
female and 29 were male. There were more females than 
males in the CD group (female/male ratio CD: 11/3, UC: 
25/26). In the control group, the female/male ratio was 15/5.
The mean disease period for the patients was 4.58±0.3 
years (1-10 years) and 4.78± 0.09 years (1-23 years) in the 
CD and UC groups, respectively. In the UC group, two 
patients had been newly diagnosed. Only three of the UC 
patients had a family history of IBD; one of them was a first 
degree relative (mother), and the other two were second 
degree relatives (aunt and cousin). A total of 24.6% of the 
patients (16 patients) were smokers, and the smoking ratio 
was higher in CD patients (7 patients or 50% in CD, 9 
patients or 17.6% in UC).
In the CD group, the disease was localized to the small 
bowel in 57.2% of the patients (8) and the ileocecal region 
in 42.8% of the patients (6). In 86.2% of UC patients, the 
disease was located in the left side of the colon, and UC had 
been documented in the rectosigmoid region of 9 patients 
in the left colon of 24 patients and in the rectum only of 11 
patients. Seven patients presented with pancolitis (Table 1).
Four of the CD patients had undergone operations due 
to ileal obstruction and one patient displayed a perianal 
abscess. One of the UC patients had undergone an operation 
for adenocarcinoma of the rectum and another one of the 
UC patients demonstrated arthritis as an extra-intestinal 
symptom. 
Investigation of the hemoglobin (hb), ESR, CRP, and 
FCP values of those groups revealed that ESR, CRP, and 
Table 1 - Patient demographics
Crohn’s Disease Ulcerative Colitis IBS (Controls) P value
Number of pts 14 51 20 P>0.05
F/M 11/3 25/26 15/5 P<0.05
Age (mean) 41.71 40.88 46.85 P>0.05
Disease period (mean) 4.58 4.78 P>0.05
Smoking 7 (50%) 9 (17.6%) P>0.05
Complication 5 pts 11 pts P>0.05
Location of disease 8 small bowel (57.2%)
6 ileocecal (42.8%)
11 rectum (21.5%)
9 rectosigmoid (17.6%)
24 left colon (48%)
7 pancolitis (12.9%)
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FCP values were higher in the IBD patients than in the 
control group, while the hb level was lower in the IBD 
group. In particular, there was a statistically significant 
difference in FCP and hb levels upon comparison of the 
IBD patients and control group (p<0.05). No statistically 
significant differences in FCP levels were detected between 
UC and CD patients (p>0.05) (Table 2). Among CD patients, 
ESR and CRP levels were significantly higher during active 
disease than in remission (p<0.05). When we investigated 
the control group and patients in remission according to the 
Crohn’s Disease Activity Index (CDAI), we found that hb 
levels were higher in controls, while ESR, CRP, and FCP 
levels were lower, and these differences were statistically 
significant (p<0.05).
Of 51 patients in the UC group, 21 were in remission 
according to the clinical Rachmilewitz endoscopic activity 
index4. Of the 32 patients with active disease, 10 were 
mild, 19 were moderate, and 3 were severe according to the 
Truelove-Witts criteria.5
Investigation of FCP levels in UC patients in remission 
and the control group showed that FCP levels were 
significantly higher in UC patients. This significant 
difference was probably due to the extremely high FCP 
levels (>230 mg/kg) in two patients. There were no 
significant differences in CRP and ESR levels between those 
two groups.
When UC patients with active disease and the control 
group were investigated, FCP levels in particular, as well as 
ESR, CRP, and UC levels were significantly higher in UC 
patients. Comparison of UC patients revealed that those with 
active disease had significantly higher ESR, CRP, and FCP 
levels than those in remission.
DISCUSSION
Inflammatory bowel diseases (IBDs) are chronic 
intestinal diseases that progress with periods of remission 
and activation. Although recently there is growing data 
regarding disease progression, diagnosis, and treatment 
options, we still are in need of easy, non-invasive, accurate, 
and inexpensive methods to estimate disease activity, 
determine therapy, and differentiate IBD flairs from IBS 
symptoms, which have been observed in 20-30% of IBD 
patients.6,7 Since the correlation between laboratory data 
and clinical activity as assessed by endoscopy and histology 
is very poor in IBD, many studies are currently focused on 
fecal markers.
In the present study, we determined the FCP levels of UC 
and CD patients and assessed IBS patients as a control group 
to illustrate the role of FCP in evaluating IBD activity and 
remission periods. Moreover, we investigated the relationship 
between FCP and other markers of inflammation.
In the present study, the mean age of patients was 41.7 
years in the CD group and 40.8 years in the UC group. The 
majority of patients were in their 2nd-4th decades of life. 
Compatible with the literature, while the number of men and 
women were similar in the UC group, the number of women 
was higher in the CD group.8, 9 Among the CD patients, five 
of the seven smokers had active disease, but only three of 
the nine UC smokers presented active disease. As noted in 
many previous studies, smoking is linked to an increased 
prevalence and risk of relapse for CD.10, 11
CDAI is a commonly used clinical and laboratory 
index for the determination of CD activity and response to 
treatment12. In the present study, all patients in remission 
according to CDAI were undergoing immunosuppressive 
treatment. The FCP levels were elevated in all of the patients 
with active disease. Many studies have previously concluded 
that there is no correlation between the clinical scenario and 
pathology in CD, or no relationship between the CDAI and 
mucosal inflammation.13
Significantly higher levels of FCP were detected in the 
IBD group compared to the control group. In the CD group, 
very high FCP levels were determined in patients with active 
disease according to CDAI clinical criteria compared with 
patients in remission and the control group. ESR and CRP 
were also higher in patients with active disease, but the 
difference in CRP was not statistically significant. FCP levels 
were also significantly higher in CD patients in remission 
than in the control group according to CDAI.
Table 2 - Hemoglobin, Erythrocyte Sedimentation Rate, C-Reactive Protein, and Fecalprotectin levels of Ulcerative Colitis, 
Crohn’s Disease, and IBS (Controls) patients
Ulcerative Colites Crohn’s Disease IBS (Controls) puc/ pcd
Hb(g/dl) 12.8 ±1.65 11.61±1.39 14.89±1.21 0.001/0.001
ESR(mm/hour) 18.64±13.51 34.94±25.56 12.30±3.62 0.043/0.001
CRP(mg/l) 17.53±21.51 33.83±38.47 4.28±3.34 0.008/0.002
FCP(mg/kg) 264.73±37.36 261.45±209.37 16.72±14.61 0.001/0.001
Puc: p value for the UC and control groups. Pcd: p value for the CD and control groups
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Leukocyte scintigraphy is the gold standard test to 
demonstrate inflammation, and it provides information 
about the localization and severity of bowel inflammation. 
Although this test is the proper method for differentiating 
functional symptoms from symptoms that are secondary 
to inflammation (and thus to estimate the response to 
treatment), the high cost and exposure to ionizing radiation 
have limited its use as a routine test. In a study performed 
by Saverymuttu et al., fecal excretion of In131-labelled 
granulocytes was higher in 89% of CD patients who were 
considered to be in remission (CDAI<150) than in IBS 
patients.14 Gaya et al. also showed a correlation between 
FCP and leukocyte scintigraphy in terms of determining the 
severity and extent of CD; in fact, FCP is more successful in 
showing intestinal inflammation than leukocyte scintigraphy. 
Moreover, there is no significant correlation between CDAI 
and FCP or leukocyte scintigraphy in determining disease 
activity.13
Roseth et al. used infliximab to treat patients with severe 
relapsing CD and found that after treatment, over a period 
of 3-4 weeks, FCP values decreased from 1000-2000 mg/L 
to 200-300 mg/L, with higher values often correlating with 
clinically active disease.6 They found that FCP values were 
normalized after treatment based on both an endoscopically 
and histologically normal mucosal lining; furthermore, 
the prognosis of patients with mucosal healing was better 
compared to non-healing patients. Therefore, those authors 
suggested that mucosal healing should be a treatment 
goal for IBD patients. The study concluded that FCP is 
a significant marker in determining disease activity and 
response to treatment in IBD patients.
The ESR, CRP, and FCP values were significantly higher 
in those UC patients with clinically and endoscopically 
active disease than in patients in remission or in the control 
group. When we investigated FCP values in UC patients 
in the remission and control groups, we found that FCP 
values were significantly higher in the UC group (p: 0.015). 
This result may be due to the FCP values of two patients in 
remission that were as high as patients with active disease 
(230, 14–240, 44). In one of those patients, the disease 
period was four years and the disease was localized to 
the left colon; in the other patient, the disease period was 
fourteen years and pancolitis had been documented. In 
the patient with UC and pancolitis adenocarcinoma of the 
rectum detected via colonoscopy during the follow-up period 
and in the other patient in remission but with high FCP the 
disease is activated one month later. Although the patients 
were considered ‘in remission’, the high FCP values showed 
continuous mucosal inflammation and high relapse risk in 
the future. Patients in clinical remission and with normal 
FCP values were also histologically in remission.
Tibble et al. used FCP values to predict relapses as well 
as to determine the necessity for IBD screening and response 
to treatment. They indicated that IBD patients in clinical 
remission with FCP values greater than 50 mg/L (in both 
the UC and CD groups) show clinical relapses within a few 
months with a sensitivity >80%.15 
Costa et al. performed a follow-up of 79 IBD patients 
in remission (CD: 31, UC: 48) for 1 year. Relapses were 
documented for 15 CD and 19 UC patients. They indicated 
that there was no significant difference in CRP and ESR 
values between patients in the relapsing and non-relapsing 
groups. However, they determined that, especially in the UC 
group, a significant difference in FCP values was present 
between the relapsing and non-relapsing groups. That study 
also showed that ESR and CRP values are not useful for 
estimating clinical relapses.7
In an investigation of more than 60 patients, Roseth et al. 
indicated that UC patients with histologically lower and higher 
disease activities can be distinguished simply on the basis of 
their FCP values. They also investigated more than 40 IBD 
patients with normal FCP values and determined mucosal 
healing in all of them. Similarly, patients in the present study 
with normal FCP values were those that were successfully 
treated and in clinical and endoscopic remission.6
Fecal calprotectin can be used as a screening test for the 
differential diagnosis of IBD and IBS. In the present study, 
all patients in the control group exhibited FCP values lower 
than the cut-off point (50 mg/ kg). To clarify a cut off point, 
Tibble et al. determined 100% sensitivity and 94% specificity 
with a cut-off point of 30 mg/kg for FCP values in a study 
comprising 225 patients. In another study of 600 patients, 
Tibble et al. determined that patients with Roma II criteria 
and normal FCP values do not have IBD and indicated 
that there is no need for those patients to be examined 
radiologically or via colonoscopy. Among all IBD patients, 
20–30% may have IBS and IBS symptoms that interfere with 
disease activity. FCP may be used to distinguish active IBD 
from IBS in those patients, and high FCP values may be used 
as a criterion for endoscopic evaluation. On the other hand, 
patients with normal FCP values are most likely to have 
functional GIS disease.
In conclusion, fecal calprotectin was found to be 
a marker that is strongly associated with colorectal 
inflammation and to indicate organic disease. This method 
is a simple and noninvasive way to assess excretion of 
PMNs and macrophages into the gut lumen, and it is not 
expensive. FCP values can be used to evaluate the response 
to treatment when screening asymptomatic patients and to 
predict relapses in IBD. 
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